June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...
AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results